- Home
- NMI vs ADCT Comparison
NMI vs ADCT Comparison
Compare NMI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | ADCT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 136.1M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NMI | ADCT |
|---|---|---|
| Price | $9.35 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 64.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $9.10 | $0.78 |
| 52 Week High | $11.28 | $4.98 |
Technical Indicators
Market Signals| Indicator | NMI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 54.98 |
| Support Level | $9.10 | $0.97 |
| Resistance Level | $10.97 | $1.87 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 63.89 | 51.25 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).